MAPT and Alzheimer disease: Accumulating evidence highlights the involvement of glycosylation in major neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), where aberrant glycosylation contributes to protein misfolding (for example, tau or α-synuclein aggregation) and impaired synaptic plasticity31,58–63.